If you want a product that will give you more CBD and offer consistent dosing, you may go for CBDPure softgels. Each capsule comes with 25 mg of full-spectrum cannabidiol.
“With no new dementia treatments in over 15 years, it is vital that we test a wide range of approaches to find effective ways to help people living with the condition,” said David Reynolds, Ph.D., of Alzheimer’s Research U.K. Reynolds underlines the importance of finding a medicine that will not only slow or stop the progression of dementia but also benefits people’s day-to-day performance.
Research shows a clear link between CBD and the reduction of inflammation and brain cell decline.
Scientists suggest that Parkinson’s disease may derive from lowered dopamine production and is most commonly expressed by muscular strains, tremors, and slow, flawed movement.
Sativex has equal amounts of THC and CBD. Hemp-derived CBD oil contains only 0.3% THC and there are no trials that would look into the effects of this cannabis solution on dementia.
Some studies suggest cannabis could help to manage a few behavioural symptoms of dementia, such as agitation and aggression.
A study is currently underway at King’s College London that will look at whether a mouth spray containing cannabinoids could be used to reduce symptoms of agitation and aggression in a small group of people with Alzheimer’s disease.
What is cannabis?
Whilst the studies in the laboratory show some promise, we need to understand the wider effects that these components have before we can know whether they have any effect – positive or negative – on the development of Alzheimer’s in people.
This is because we have not received any high-quality applications from researchers intending to investigate these issues.
The jury is still out on whether cannabis or its by-products could be used to treat dementia. A lack of strong research studies mean that dubious and anecdotal reports have taken the place of hard evidence.
Denver, Colorado, March 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), (“CBD Global” or the “Company”), is pleased to share that a recent study has revealed that CBD may be key to stopping triggers for Alzheimer’s disease, according to researchers from the Medical College of Georgia in Augusta University.
CBD Global Sciences, Inc., is a vertically integrated hemp-based CBD producer and branding investment vehicle which currently owns two product categories, branded under the name Aethics™ (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products. CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.
For further information, please contact Investor Relations, (888) 401-2239, [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
ABOUT CBD GLOBAL SCIENCES INC.